Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Part of paid clinical trials in Birmingham, Alabama.

Sponsor: Priothera SAS
Study ID: NCT05429632
Phase: PHASE3
Status: Recruiting

Apply to this trial

Conditions

Adult Acute Myeloid Leukemia

Eligibility Criteria

Sex: ALL
Age: 18 Years - 75 Years
Healthy Volunteers: Not accepted

Interventions

mocravimod — DRUG
S1PR modulator

Study Details

This is a multi-center, randomized, double-blinded, placebo controlled trial.

Key Dates

Start date: Jun 16, 2022
Status verified: Dec 2025
Primary completion: May 31, 2027
Completion: Nov 30, 2029

Study Design

Enrollment: 366 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: 3mg mocravimod arm
3 mg of mocravimod orally once per day for 12 months
Experimental: 1mg mocravimod arm
1 mg of mocravimod orally once per day for 12 months
Placebo Comparator: Placebo arm
placebo orally once per day for 12 months

Primary Outcome Measure

Relapse-free survival (RFS) [ Time Frame: 12 months ]

Central Contacts

Malika Souquieres, MSc
+33 (0) 6 40 91 26 76
[email protected]
Jens Hasskarl, MD
+41 79 5432099
[email protected]

Locations (21)

Facility	City	State	ZIP	Site coordinators
University of Alabama Hospital (UAB Hospital)	Birmingham	Alabama	35233-1932	Antonio Di Stasi, MD [email protected]
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234-2165	-
City of Hope Comprehensive Cancer Center - Duarte	Duarte	California	91010	Vaibhav Agrawal, MD [email protected]
University of California Los Angeles (UCLA) - David Geffen School of Medicine	Los Angeles	California	90095	Steven Tsai, MD [email protected]
UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center	Aurora	Colorado	80045	-
Moffitt Cancer Center	Tampa	Florida	33612	Asmita Mishra, MD [email protected]
Emory University - Winship Cancer Institute (WCI)	Atlanta	Georgia	30322-1013	Edmund Waller, MD [email protected]
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242	Kittika Poonsombudlert, MD [email protected]
University of Kansas Cancer Center	Westwood	Kansas	66103	Haitham Abdelhakim, MD [email protected]
Ochsner Medical Center (OMC) - New Orleans	New Orleans	Louisiana	70121	-
University of Maryland Medical Center (UMMC)	Baltimore	Maryland	21201-1544	Jean Yared, MD [email protected]
Massachusetts General Hospital	Boston	Massachusetts	02114	-
Henry Ford Cancer Institute	Detroit	Michigan	48202-2610	Shatha Farhan, MD [email protected]
Spectrum Health Medical Group (SHMG) - Blood & Marrow Transplant - Adult (BMT)	Grand Rapids	Michigan	49503	Sami Brake, MD [email protected]
University of Rochester Medical Center (URMC)	Rochester	New York	14642	Eric Huselton, MD [email protected]
Stony Brook University (SBU) - Cancer Center	Stony Brook	New York	11794-0001	Fengshuo Lan, MD [email protected]
University of Cincinnati Medical Center (University Hospital)	Cincinnati	Ohio	45267	Edward Faber, MD [email protected] 513-584-4268
The Ohio State University Comprehensive Cancer Center (OSUCCC)	Cleveland	Ohio	44106-1716	Sarah Wall, MD [email protected]
Oregon Health & Science University (OHSU) - Knight Cancer Institute	Portland	Oregon	97239-3098	Arpita Gandhi, MD [email protected]
University of Pennsylvania - Abramson Cancer Center	Philadelphia	Pennsylvania	19104-4206	-
Baylor Charles A. Sammons Cancer Center	Dallas	Texas	75246	Jane Reynolds, MD [email protected]

Find similar trials in Birmingham, AL

By research site

University of Alabama Hospital (UAB Hospital)· Birmingham, AL Banner MD Anderson Cancer Center· Gilbert, AZ City of Hope Comprehensive Cancer Center - Duarte· Duarte, CA University of California Los Angeles (UCLA) - David Geffen School of Medicine· Los Angeles, CA UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center· Aurora, CO Moffitt Cancer Center· Tampa, FL